DC federal court declines restraining order sought by Apotex

The District of Columbia federal court has declined to issue a temporary restraining order and preliminary injunction sought by Apotex to stop the FDA from delaying approval of its generic form of AstraZeneca's Prilosec. Apotex had sought to defeat a pediatric exclusivity patent extension on Prilosec.
You must be a registered member of MMM to post a comment.
close

Next Article in Careers

Email Newsletters


What does going "beyond the pill" actually mean? At MM&M's recent inaugural spring conference, audience members heard from real-world companies that are managing the organizational, technological, and promotional challenges inherent in this transition, such as partnering with health neophytes, harnessing technologies that allow deeper engagement with patients, and adopting a new commercial mindset to serve, not sell. Download here.


A wave of more effective anti-cancer drugs has set the oncology world on fire with enthusiasm. While many hail this as a new era, an equally vocal faction questions the money spent for the value gained. This medical and commercial trend report for marketers of anti-cancer modalities touches on many of the latest shifts that have expedited product launches and otherwise impacted promotion and reimbursement of these drugs. Click here.